Health
Combo monoclonal antibody drugs may lower coronavirus loads – CIDRAP
Bamlanivimab paired with etesevimab was more effective than bamlanivimab alone.
Mildly to moderately ill COVID-19 adult outpatients given a combination of the monoclonal antibodies bamlanivimab and etesevimab early in the disease had significantly lower viral loads at day 11 than those who received a placebo, but a similar effect was not seen in those given bamlanivimab alone, a study published today in JAMA finds.
Bamlanivimab manufacturer Eli Lilly sponsored the double-blind phase 2/3 BLAZE-1 clinical trial, which involved 533 COVID-19 patients at 49 US medical centers. The…
-
Noosa News15 hours agoHockey coach in Arana Hills charged with grooming and sexual offences against teenage girls
-
Noosa News16 hours agoDepartment of Transport and Main Roads orders shutdown of North Ipswich Free Shop
-
General15 hours agoWoman killed and man injured in shark attack on NSW Mid North Coast
-
General24 hours agoFormer Marine Paul Doyle pleads guilty to Liverpool FC parade car ramming charges